Rivaroxaban to prevent blood clots in hypertrophic cardiomyopathy

Trial details

Who runs it

Rennes University Hospital

Trial code

NCT07202897EU 2024-511084-28-00

Record updated

12 June 2026

Original description

Hypertrophic cardiomyopathy (HCM) is a common (> 1/500 in the general adult population) genetically transmitted disease impacting markedly patients' lives from the early ages to the latest. The phenotype as the prognosis of HCM may greatly differ from one patient to another: most patients present no or few symptoms and a near-normal lifespan, while others are severely symptomatic. Paroxysmal, persistent or permanent atrial fibrillation (AF) is frequent in HCM, occurring in more than 20%-25% of patients and is often considered as an important turning point for the quality of life of these patients. AF decreases cardiac output and exercise tolerance, increases hospitalization rate, and markedly increase the risk of embolic stroke with the need for life-anticoagulation. It has been shown that stroke may precede AF discovery and that it may occur at young ages with devastation consequences. AF also may trigger sudden cardiac death.Read full original descriptionShow less

LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain: A Randomized Multicenter Trial

Hypertrophic cardiomyopathy (HCM) is a common (> 1/500 in the general adult population) genetically transmitted disease impacting markedly patients' lives from the early ages to the latest. The phenotype as the prognosis of HCM may greatly differ from one patient to another: most patients present no or few symptoms and a near-normal lifespan, while others are severely symptomatic. Paroxysmal, persistent or permanent atrial fibrillation (AF) is frequent in HCM, occurring in more than 20%-25% of patients and is often considered as an important turning point for the quality of life of these patients. AF decreases cardiac output and exercise tolerance, increases hospitalization rate, and markedly increase the risk of embolic stroke with the need for life-anticoagulation. It has been shown that stroke may precede AF discovery and that it may occur at young ages with devastation consequences. AF also may trigger sudden cardiac death.

Observational studies have been conducted to search for parameters which correlate with the risk of AF (P wave duration and supra-ventricular burst on the Holter-ECG monitoring, L-wave morphology, degree of hypertrophy, clinical parameters-comorbidities, and size of the left atrium) with no real impact on clinical management. Left Atrial strain (LA-strain) has been recently demonstrated relevant (for instance our pilot work (for predicting stroke and/or AF (a cut-off of 15% is highly specific, 20% being the optimal cut-off). LA-strain (cut-off 20%) could be used for defining the patients that might require preventive anticoagulation therapy.

A randomized clinical trial is needed to extend the use of anticoagulation therapy to patients in sinus rhythm but identified to be at risk for AF.

Of note, it has been demonstrated that in this population, stroke occurred in 67% of the patients without any clinical atrial arrhythmia.

Inclusion: 40 - 80 years of age; 50 and 120 kg of weight; In sinus rhythm; Prior confirmed diagnosis of "primary" hypertrophic cardiomyopathy; Left Atrial reservoir strain measured ≤20% (corelab confirmation); Signature of an informed consent; Highly effective contraceptive methods for women of childbearing potential from at least 14 days prior to start treatment, throughout the study treatment period, and until at least 4 weeks after the last dose of study medication.

Exclusion: Any anticoagulation therapy in the 15 days prior to enrollment; Any cardiac surgery in the 30 days prior to enrollment; Any major bleeding in the 90 days prior to enrollment; Need to be on dual antiplatelet therapy (aspirin >100 mg daily and a P2Y12 inhibitor, i.e. clopidogrel, ticagrelor, prasugrel…); Ischemic stroke or intracranial hemorrhage in the 30 days prior to enrollment; Concomitant combined strong P-gp and CYP3A4 inducers or inhibitors; Secondary hypertrophic cardiomyopathy (aortic stenosis, hypertension, amyloidosis and all phenocopies…); Signs of heart failure; Documented atrial arrhythmia; Known hypersensitivity or others contraindications to Rivaroxaban (refer to contraindications); Active cancer or life expectancy less than 3 years; Creatinine clearance <30 mL/min (Cockcroft); Hospitalization; Uncontrolled blood pressure; Severe liver dysfunction, cirrhosis Child B or C; Contraindication for a brain magnetic resonance imaging exam; Active endocarditis at the time of enrollment; Non-compliant; Participation in another interventional clinical trial; Protected person (adults legally protected (under judicial protection, guardianship or supervision), person deprived of their liberty, pregnant woman, lactating woman or planning pregnancy during the study period and minor); Absence of coverage by a social security scheme.

ClinicalTrials.gov NCT07202897 · EU CTIS 2024-511084-28-00